At months 4 and 16, lower S100A8/9 and S100A12 levels with or without lower CRP resulted in numerically higher odds of correctly predicting JIA-ACR ID response in patients receiving abatacept with MTX compared with patients receiving abatacept alone. This evidence concerns the gene S100A8 and juvenile idiopathic arthritis.